preclinical therapeutics development

Kayothera, Inc. is a preclinical therapeutics company developing first-in-class, orally-available small molecule inhibitors of the retinoid and rexinoid nuclear receptor pathways. Its approach blocks the formation of retinoid or rexinoid nuclear ligands, targeting pathways that drive cardiometabolic and cancer outcomes. The company is developing medicines for diabetes, obesity and other unmet medical needs, and has nominated KAYO-1732 as a development candidate for type 2 diabetes and cardiometabolic indications.

Read more

small molecule drug discovery